Arena nets $2m upfront for Taiwan Belviq rights
This article was originally published in Scrip
Executive Summary
Arena Pharmaceuticals has licensed the marketing and distribution rights to its obesity drug Belviq (lorcaserin) in Taiwan to the local firm CY Biotech, as part of a continuing global push to expand potential commercial territories for the product.